君实生物(688180.SH):上半年净亏损4.13亿元
Core Insights - Junshi Biosciences (688180.SH) reported a revenue of 1.168 billion yuan for the first half of 2025, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders was 413 million yuan, an improvement from a net loss of 645 million yuan in the same period last year [1] - The company has made progress in the discovery, research and development, production, and commercialization of innovative drugs, but has not yet achieved profitability [1] - Junshi Biosciences continues to advance its pipeline of products under development and plans to maintain its investment in research and development [1]